Pre-Made Clervonafusp Alfa Biosimilar, Fusion Protein targeting SLC29A2/ENT2 fused with human GAA (glucosidase alpha, acid, lysosomal alpha-glucosidase )(Pr67-952) (1:2) Enzyme substitute: Recombinant therapeutic protein targeting DER12/HNP36 is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Clervonafusp Alfa is consisting of immunoglobulin G1-kappa, cell-penetrating humanized Fab fragment targeting the equilibrative nucleoside transporter 2 (ENT2), fused with a human lysosomal ¦Á-glucosidase fragment, glycoform alfa. It is used to treat Pompe disease.